Clinical Trials Logo

Stimulant Use Disorder clinical trials

View clinical trials related to Stimulant Use Disorder.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06444256 Not yet recruiting - Clinical trials for Stimulant Use Disorder

Orexin Receptor Antagonism and Sleep in Stimulant Use Disorder

Start date: June 30, 2024
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine the effects of suvorexant (SUVO), on sleep, stress, and drug craving during early abstinence from stimulants and to determine the effects of treatment (SUVO vs. treatment as usual (TAU)) on post-treatment (Days 13-30) residential program length of stay (LOS) and completion rate.

NCT ID: NCT06323837 Not yet recruiting - Clinical trials for Stimulant Use Disorder

Mirtazapine for the Treatment of Methamphetamine Use in Opioid Use Disorder Patients Receiving Medication Assisted Treatment

MIRROM
Start date: April 1, 2024
Phase: Phase 2
Study type: Interventional

This project will evaluate the ability of Mirtazapine (MZP), a pharmacologically unique medication with a growing body of evidence to support its efficacy and safety for the treatment of methamphetamine (MA) use among medication for opioid use disorder (MOUD) patients, to significantly decrease MA use and related health-impairing behaviors. MZP has already successfully been used in the treatment of methamphetamine (detailed further below and in the Appendices). The investigators hypothesize that those assigned to the MZP plus treatment as usual (TAU) MZP+TAU arm will demonstrate significantly increased rates of biochemically verified abstinence from MA and other substances of abuse and experience improvements in health impairing behaviors relative to the placebo (PLO)+TAU arm across the 10-week treatment and follow-up periods.